PHYSIOMICS PLC - Investor Update

Physiomics PLC (PYC:AIM) delivered a positive investor update highlighting strong company performance despite challenging life sciences market conditions, with record revenue growth, a best ever first half, and a robust order book supported by 23 projects across 13 clients. The company reported significant year on year revenue increases and expects to achieve record total income, driven by its dual service lines in modelling and simulation and its newly launched biometrics offering, both contributing to diversified revenue streams and improved margins. Management emphasized a clear growth strategy focused on expanding its client base, increasing repeat business, and leveraging high value consultancy expertise, while maintaining a healthy pipeline with a solid conversion rate. Strategic initiatives including investment in AI, data systems, and quality management aim to enhance operational efficiency and support long term EBITDA growth. While macroeconomic headwinds and biotech funding constraints persist, Physiomics sees improving market conditions and remains focused on organic growth, potential M and A opportunities, and progression of its dosing software asset. The board also addressed governance matters, reaffirming confidence in its strategy to drive shareholder value and sustainable profitability.